Evidence map›Paper›PMID 21594797›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2011

Biochemical and biophysical approaches to probe CFTR structure.

André Schmidt, Juan L Mendoza, Philip J Thomas

Abstract read
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
13.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

André SchmidtDepartment of Physiology, University of Texas Southwestern Medical Center, Dallas, TX 75390-9040, USA. andre.schmidt@utsouthwestern.edu
Juan L Mendoza
Philip J Thomas
The University of Texas Southwestern Medical Center · US

Funding

DEVELOPMENT OF MEMBRANE PROTEIN STRUCTURER37DK049835 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI THOMAS, PHILIP J · 2008 to 2017
$3.6M
NIDDK NIH HHS R37 DK049835
6 · The paper itself

Abstract

The cystic fibrosis transmembrane regulator (CFTR) is a multi-domain integral membrane protein central to epithelial fluid secretion (see Chapter 21). Its activity is defective in the recessive genetic disease cystic fibrosis (CF). The most common CF-causing mutation is F508del in the first nucleotide binding domain (NBD1) of CFTR. This mutation is found on at least one allele of more than 90% of all CF patients. It is known to interfere with the trafficking/maturation of CFTR through the secretory pathway, leading to a loss-of-function at the plasma membrane. Notably, correction of the trafficking defect by addition of intragenic second-site suppressor mutations, or the alteration of bulk solvent conditions, such as by reducing the temperature or adding osmolytes, leads to appearance of functional channels at the membrane--thus, the rescued F508del-CFTR retains measurable function. High-resolution structural models of NBD1 from X-ray crystallographic data indicate that F508 is exposed on the surface of the domain in a position predicted by homologous ABC transporter structures to lie at the interface with the intracellular loops (ICLs) connecting the transmembrane spans. Determining the relative impact of the F508del mutation directly on NBD1 folding or on steps of domain assembly or both domain folding and assembly requires methods for evaluating the structure and stability of the isolated domain.

Indexed as

AnimalsBiochemistryBiophysicsCircular DichroismCrystallography, X-RayCystic Fibrosis Transmembrane Conductance RegulatorHumansMiceNucleotidesProtein DenaturationProtein StabilityProtein Structure, TertiarySpectrometry, FluorescenceTemperatureCystic Fibrosis Transmembrane Conductance RegulatorNucleotides

Identifiers

PMID21594797
PMCPMC3266684
OpenAlexW104012070

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.